PIK3CA and ovarian cancer: Twenty-eight out of 42 evaluable patients had PIK3CA mutations, among whom the confirmed ORR was 14.3% (4/28) with a confirmed response observed in patients with breast cancer (2/5, 40%) and ovarian cancer (2/5, 40%), and a DCR of 46.4% (13/28).